相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Development of Allosteric BRAF Peptide Inhibitors Targeting the Dimer Interface of BRAF
Amber Y. Gunderwala et al.
ACS CHEMICAL BIOLOGY (2019)
Biochemical Characterization of Full-Length Oncogenic BRAFV600E together with Molecular Dynamics Simulations Provide Insight into the Activation and Inhibition Mechanisms of RAF Kinases
Nicholas Cope et al.
CHEMBIOCHEM (2019)
STAT3 inhibitor sensitized KRAS-mutant lung cancers to RAF innioitor by activating MEK/ERK signaling pathway
Zhenlin Wang et al.
AGING-US (2019)
Cryo-EM structure of a dimeric B-Raf:14-3-3 complex reveals asymmetry in the active sites of B-Raf kinases
Yasushi Kondo et al.
SCIENCE (2019)
Architecture of autoinhibited and active BRAF-MEK1-14-3-3 complexes
Eunyoung Park et al.
NATURE (2019)
Mechanism of BRAF Activation through Biochemical Characterization of the Recombinant Full-Length Protein
Nicholas Cope et al.
CHEMBIOCHEM (2018)
The AMPK inhibitor overcomes the paradoxical effect of RAF inhibitors through blocking phospho-Ser-621 in the C terminus of CRAF
Jimin Yuan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2018)
N-(7-Cyano-6-(4-fluoro-3-(2-(3-(trifluoromethyl)phenypacetamido)phenoxy)benzo[d]thiazol-2-yl)cyclopropanecarboxamide (TAK632) Promotes Inhibition of BRAF through the Induction of Inhibited Dinners
Michael Grasso et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Type II RAF inhibitor causes superior ERK pathway suppression compared to type I RAF inhibitor in cells expressing different BRAF mutant types recurrently found in lung cancer
Noeparast Amir et al.
Oncotarget (2018)
A Braf kinase-inactive mutant induces lung adenocarcinoma
Patricia Nieto et al.
NATURE (2017)
Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS
Zhan Yao et al.
NATURE (2017)
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity
Matthew T. Chang et al.
NATURE BIOTECHNOLOGY (2016)
Chemically Linked Vemurafenib Inhibitors Promote an Inactive BRAFV600E Conformation
Michael Grasso et al.
ACS CHEMICAL BIOLOGY (2016)
An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling
Zoi Karoulia et al.
CANCER CELL (2016)
The Dark Side of Cell Signaling: Positive Roles for Negative Regulators
Mark A. Lemmon et al.
CELL (2016)
Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120
Shih-Hsun Chen et al.
CANCER DISCOVERY (2016)
Non-p.V600E BRAF Mutations Are Common Using a More Sensitive and Broad Detection Tool
Jamal Carter et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2015)
BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition
Zhan Yao et al.
CANCER CELL (2015)
RAF inhibitors that evade paradoxical MAPK pathway activation
Chao Zhang et al.
NATURE (2015)
Regulation of RAF protein kinases in ERK signalling
Hugo Lavoie et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2015)
Crystal structure of a BRAF kinase domain monomer explains basis for allosteric regulation
Neroshan Thevakumaran et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2015)
Kinases and Pseudokinases: Lessons from RAF
Andrey S. Shaw et al.
MOLECULAR AND CELLULAR BIOLOGY (2014)
Dynamic architecture of a protein kinase
Christopher L. McClendon et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
RAF Inhibitors Activate the MAPK Pathway by Relieving Inhibitory Autophosphorylation
Matthew Holderfield et al.
CANCER CELL (2013)
Allosteric Activation of Functionally Asymmetric RAF Kinase Dimers
Jiancheng Hu et al.
CELL (2013)
Identification of a Novel Family of BRAFV600E Inhibitors
Jie Qjn et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Crystal structures of the JAK2 pseudokinase domain and the pathogenic mutant V617F
Rajintha M. Bandaranayake et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2012)
Mutation that blocks ATP binding creates a pseudokinase stabilizing the scaffolding function of kinase suppressor of Ras, CRAF and BRAF
Jiancheng Hu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
Sonja J. Heidorn et al.
CELL (2010)
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
Poulikos I. Poulikakos et al.
NATURE (2010)
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
Georgia Hatzivassiliou et al.
NATURE (2010)
The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner
Eric W. Joseph et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
A dimerization-dependent mechanism drives RAF catalytic activation
Thanashan Rajakulendran et al.
NATURE (2009)
Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3
Natalia Jura et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
ATP and MO25 alpha Regulate the Conformational State of the STRAD alpha Pseudokinase and Activation of the LKB1 Tumour Suppressor
Elton Zeqiraj et al.
PLOS BIOLOGY (2009)
Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma
Clara Montagut et al.
CANCER RESEARCH (2008)
Selective Raf inhibition in cancer therapy
Vladimir Khazak et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2007)
Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF
PTC Wan et al.
CELL (2004)
Mutations of the BRAF gene in human cancer
H Davies et al.
NATURE (2002)
分享论文
